S&P 500 7,457.69 -1.01% NASDAQ 25,520.24 -1.40% DOW 52,146.42 -0.77% R2K 2,962.22 -0.42% VIX 18.77 +12.19% US 10Y 4.54 -0.61% DXY 100.75 +0.02% GOLD 4,012.70 +0.68% CRUDE 82.49 +4.48%
Next Bullish Trade
Sign in
TXG

10x Genomics, Inc. TXG

$43.74 -0.74 (-1.66%)
Extended · +1.70σ

Price chart

Timeframe
Range
Fundamentals · free Click ▲ earnings markers (daily) for the day's move

Loading…

Latest bar · TXG

Momentum reads · latest daily bar
Last
$43.74
-0.74 (-1.66%)
Mkt cap
$5.6B
Healthcare
RSI(14)
66.7
neutral
Stochastic %K
85.5
overbought
MFI(14)
64.8
neutral
ADX(14)
46.7
trending

Green means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.

Financial overlay · last 12 quarters

The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.

QuarterRevenue Net incomeOp income FCFNet margin Op margin
2026-03-31 $0.2B $-0.0B $-0.0B $0.0B -8.9% -11.3%
2025-12-31 $0.2B $-0.0B $-0.0B $0.0B -9.8% -11.8%
2025-09-30 $0.1B $-0.0B $-0.0B $0.0B -18.4% -21.6%
2025-06-30 $0.2B $0.0B $-0.0B $0.0B 20.0% -6.1%
2025-03-31 $0.2B $-0.0B $-0.0B $0.0B -22.2% -31.3%
2024-12-31 $nanB $nanB $nanB $nanB nan% nan%

Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.

Compare TXG vs peers

Line TXG up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.

Comparing TXG no peers yet — add up to 4 below

Add tickers to compare with TXG

~30 metrics across Snapshot, OdysseyHQ zone, Valuation, Growth, Quality, Technicals, Sentiment, and Risk — with a weighted score and a one-line read on each.

Earnings replay · last 20 reports

How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.

DateEPS actual EPS estSurprise Next-day
2026-05-07 0.07 -0.06 +219.2% -3.7%
2026-02-12 0.07 -0.04 +276.2% +3.5%
2025-11-06 -0.02 -0.07 +67.4% +17.3%
2025-08-07 0.48 -0.08 +702.1% -4.0%
2025-05-08 -0.10 -0.29 +64.9% +1.6%
2025-02-12 -0.14 -0.11 -27.1% -0.5%
2024-10-29 -0.02 -0.26 +94.1% +4.4%
2024-08-08 0.01 -0.23 +102.2% +4.5%
2024-04-30 -0.20 -0.39 +48.3% -8.1%
2024-02-15 0.08 -0.02 +502.5% +0.8%
2023-11-02 -0.10 -0.04 -141.0% +8.7%
2023-08-03 -0.14 -0.05 -186.4% -4.2%
2023-05-03 -0.07 -0.16 +54.7% +1.3%
2023-02-15 0.21 -0.20 +202.1% +11.2%
2022-11-02 -0.07 -0.24 +69.3% +18.5%
2022-08-08 -0.25 -0.30 +16.5% +3.3%
2022-05-04 -0.14 -0.33 +56.8% -4.0%
2022-02-16 -0.16 -0.03 -380.1% -14.7%
2021-11-03 -0.15 -0.21 +28.6% +11.2%
2021-08-04 -0.11 -0.23 +53.9% -5.2%

Earnings markers are overlaid on the daily price chart above. Click a ▲ marker for that day's move.

Peer comparison · Healthcare

Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.

Ticker ⇅ Mkt cap ⇅ P/E ⇅ Fwd P/E ⇅ P/S ⇅ EV/EBITDA ⇅ P/B ⇅ Gross M ⇅ Rev gr ⇅ EPS gr ⇅ FCF yld ⇅
TXG $6B 211.6 8.7 -166.1 7.0 69.7% -2.6% 2.24%
LLY $1,051B 41.5 26.3 14.6 30.1 33.8 82.8% 55.5% 169.9% 0.87%
UNH $387B 31.8 19.2 0.9 20.2 4.0 18.8% 2.0% 0.7% 4.57%
JNJ $609B 29.0 19.7 6.2 18.4 7.5 68.1% 6.6% -1.0%
MRK $315B 36.0 13.2 4.8 12.1 6.9 76.7% 4.9% 4.46%
ABBV $450B 124.8 15.6 7.2 17.2 -67.6 72.0% 12.4% -46.2% 4.63%
PFE $143B 19.1 8.8 2.3 7.6 1.6 74.8% 5.4% -10.1% 8.67%
TMO $198B 29.8 19.5 4.4 21.1 3.8 40.9% 6.2% 11.3% 2.79%

Auto-seeded from sector. Click any ticker to switch.

Ownership

Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.

Top institutional holders

Top-10 concentration: 63.5%

HolderShares% out
FMR, LLC 17,740,972 15.18%
ARK Investment Management, LLC 11,717,317 10.03%
Blackrock Inc. 10,079,913 8.62%
Vanguard Portfolio Management LLC 6,912,936 5.91%
Quantinno Capital Management, LP 5,411,761 4.63%
Vanguard Capital Management LLC 5,269,586 4.51%
Sumitomo Mitsui Trust Group, Inc. 5,110,214 4.37%
Amova Asset Management Americas Inc 5,104,178 4.37%
Goldman Sachs Group Inc 3,971,800 3.40%
Geode Capital Management, LLC 2,904,228 2.48%

Insider activity · 90d

6 buys / 8 sells · ratio 0.75 · Finnhub

  • Saxonov Serge SELL 1,108,380 @ $36.16
  • Saxonov Serge SELL 1,110,041 @ $35.32
  • Saxonov Serge SELL 1,119,862 @ $34.28
  • Saxonov Serge SELL 1,129,853 @ $33.29
  • Teichmann Sarah A. BUY 35,609
  • SULIMAN SHEHNAAZ BUY 37,445
  • Kosaraju Sridhar BUY 65,278
  • MATEO ALAN BUY 85,877
  • Popovits Kimberly J BUY 37,445
  • STUELPNAGEL JOHN R BUY 368,436

Analyst estimates

Finnhub

What Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.

Low
$20.0
Mean
$37.15385
High
$50.0
Analysts
13
Recommendation distribution · period 2026-07-01
5
4
11
Revision trend (2026-04-01 → 2026-07-01): net 9 → 9 0 (net = strong_buy+buy − sell−strong_sell)

SEC filings

The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.

FormFiled DescriptionAction
4 2026-06-24 Insider transaction (Form 4) view ·
4 2026-06-18 Insider transaction (Form 4) view ·
4 2026-06-08 Insider transaction (Form 4) view ·
4 2026-06-08 Insider transaction (Form 4) view ·
4 2026-06-08 Insider transaction (Form 4) view ·
4 2026-06-08 Insider transaction (Form 4) view ·
4 2026-06-08 Insider transaction (Form 4) view ·
4 2026-06-08 Insider transaction (Form 4) view ·
8-K 2026-06-08 8-K view ·
4 2026-05-27 Insider transaction (Form 4) view ·
4 2026-05-27 Insider transaction (Form 4) view ·
4 2026-05-27 Insider transaction (Form 4) view ·
10-Q 2026-05-08 10-Q view ·
8-K 2026-05-07 8-K view ·
DEF 14A 2026-04-24 DEF 14A view ·
4 2026-04-16 Insider transaction (Form 4) view ·
4 2026-03-25 Insider transaction (Form 4) view ·
4 2026-03-04 Insider transaction (Form 4) view ·
4 2026-03-02 Insider transaction (Form 4) view ·
4 2026-03-02 Insider transaction (Form 4) view ·
4 2026-03-02 Insider transaction (Form 4) view ·
4 2026-02-27 Insider transaction (Form 4) view ·
4 2026-02-25 Insider transaction (Form 4) view ·
4 2026-02-25 Insider transaction (Form 4) view ·
4 2026-02-25 Insider transaction (Form 4) view ·
10-K 2026-02-13 10-K view ·
8-K 2026-02-12 8-K view ·
8-K 2026-01-12 8-K view ·
4 2026-01-07 Insider transaction (Form 4) view ·
4 2025-11-25 Insider transaction (Form 4) view ·
4 2025-11-25 Insider transaction (Form 4) view ·
4 2025-11-25 Insider transaction (Form 4) view ·
8-K 2025-11-14 8-K view ·
10-Q 2025-11-07 10-Q view ·
8-K 2025-11-06 8-K view ·
4 2025-09-16 Insider transaction (Form 4) view ·
4 2025-08-26 Insider transaction (Form 4) view ·
4 2025-08-26 Insider transaction (Form 4) view ·
4 2025-08-26 Insider transaction (Form 4) view ·
10-Q 2025-08-08 10-Q view ·
8-K 2025-08-07 8-K view ·
4 2025-06-11 Insider transaction (Form 4) view ·
4 2025-06-05 Insider transaction (Form 4) view ·
4 2025-06-05 Insider transaction (Form 4) view ·
4 2025-06-05 Insider transaction (Form 4) view ·
4 2025-06-05 Insider transaction (Form 4) view ·
4 2025-06-05 Insider transaction (Form 4) view ·
4 2025-06-05 Insider transaction (Form 4) view ·
8-K 2025-06-05 8-K view ·
4 2025-06-02 Insider transaction (Form 4) view ·
4 2025-05-27 Insider transaction (Form 4) view ·
4 2025-05-27 Insider transaction (Form 4) view ·
4 2025-05-27 Insider transaction (Form 4) view ·
8-K 2025-05-14 8-K view ·
10-Q 2025-05-09 10-Q view ·
8-K 2025-05-08 8-K view ·
DEF 14A 2025-04-14 DEF 14A view ·
4 2025-03-19 Insider transaction (Form 4) view ·
4 2025-03-19 Insider transaction (Form 4) view ·
4 2025-03-19 Insider transaction (Form 4) view ·

About TXG

10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3' gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without t…

Options picks · TXG

ITM + OTM ideas from the latest scan

Loading…

Congress trades · TXG

STOCK Act disclosures

Loading…

SEC filings & insiders · TXG

EDGAR · live

Loading…

Holders · TXG

Institutions & insider activity

Loading…